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Abstract 
Objective: Treatment of stress urinary incontinence consists of a wide range of options, from conservative therapies like 
lifestyle changes, medication, pelvic floor muscles exercises, electro-stimulation, to minimally invasive procedures- injection of 
collagen, suburethral slings TVT / TOT and last but not least, invasive surgical treatment reserved for recurrent and complex cases. 
Among the latest minimally invasive procedures reported in literature, the injection of intra-and perisphincterian of autologous stem 
cell (mioblasts and /or mature fibroblasts grown and multiplied in the laboratory from biopsy samples taken from the pectoralis 
muscles).  
Material and method: On October 18, 2010, in “Fundeni” Clinical Institute of Uronephrology and Renal Transplantation 
was performed the first stem cell implantation procedure in the urethral sphincter, in Romania.  
Results: Assessment at 6 weeks, the quality of life questionnaires, micturition diary and clinical examination revealed a 
stunning decrease of  urine loss from 6 pads / day at one per day, which significantly improved the patient’s quality of life.  
Conclusions: Stem-cell- mioblasts therapy may represent in the future an every-day intervention in the urologist’s 
armamentarium. The effectiveness of this treatment can change the course of therapy and last but not least, the accessibility to 
urological evaluation of patients with stress urinary incontinence. Clinical and urodynamic evaluations will continue and will be future 
scientific topics. 
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Introduction 
Stress urinary incontinence is a 
symptom/sign/condition that is defined by involuntary loss 
of urine that occurs during physical activity, with the effort 
of coughing, sneezing, laughing, prolonged standing, 
sexual activity, etc. [1]. Although not life threatening, it is 
certainly a public health problem, affecting the quality of 
life, mainly of the female population. The prevalence of 
this disorder reaches alarming rates, about 20% of total 
female population being affected, percentages increasing 
to 35% for those aged over 60 years [2, 3]. 
Urinary continence and the act of micturition 
depend on the normal functioning of the lower urinary 
tract and of the nervous system. Two muscular structures 
are mainly involved in controlling the act of micturition: 
- the urethral sphincter, which must be fully 
functional in order to facilitate continence and micturition; 
- the detrusor, the bladder muscle layer, which 
should gradually relax to allow the filling of the bladder 
and to contract efficiently in order to eliminate the urine. 
Whenever the pelvic floor structures are 
impaired, the base of the bladder and the urethra would 
weaken, with the appearance of urinary incontinence due 
to the increasing of the abdominal pressure during efforts 
(coughing, laughing, sneezing, exercise). In addition, it 
has been described an entity in which the components of 
the pelvic floor are not affected, still the urine loss 
persists, the mechanism being described as intrinsic 
sphincter deficiency [1]. 
Among the most important risk factors reported 
in the occurrence of stress urinary incontinence (SUI) are 
mentioned: female sex, multiparity, obstetric history, 
lifestyle, chronic cough (chronic bronchitis, asthma), 
advanced age, estrogen status, obesity and history of 
pelvic surgery [4, 5, 6, 7, 8]. 
The treatment of SUI consists in a wide range of 
options, from conservative therapies including lifestyle 
changes, medication, pelvic floor muscles exercises, 
electrostimulation to minimally invasive - injection of 276 
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Posterior compartment prolapse and anal incontinence 
are evaluated by the general surgeon or proctologist, 
uterine and vaginal prolapse, dyspareunia by the 
gynecologist and cystocele and low urinary tract 
symptoms by the urologist. Urinary incontinence and 
pelvic floor prolapse are two pathological entities that 
occur as a result of structural damage to several 
components of the urogenital diaphragm. Thus, according 
to the first symptoms that appear, the first presentation to 
the doctor, the outcome of treatment, follow-up are carried 
out by the specialist who treated only a symptom for 
which the patient initially presented, though as we 
mentioned above, the pathogenesis is multifactorial and 
the symptoms appear after the breakdown of the 
structures with a high grade of fragility. For this reason, 
many patients receive an incomplete treatment, which 
often worsens the clinical background or trigger other 
symptoms caused by other structures which, at the time 
of presentation, were compensated. 
Suburethral slings, inserted transobturatory, 
were introduced in Europe several years ago. This 
procedure was carried out by urogynecologist despite the 
absence of long-term data regarding efficiency and the 
rate of healing. The same thing happened with TVT's 
when they were introduced and, although the medium and 
long term data were lacking, they were adopted and 
became today's gold-standard treatment for SUI in 
women. Abdel-Fattah has recently published a series of 
reports [14, 15] that assessed physicians’ preferences for 
minimally invasive treatment of stress urinary 
incontinence. The results were encouraging and 
emphasized that one third of respondents considered that 
TVT-O was a procedure up-to-date and must be applied 
immediately, while others expect the medium and long 
term statistics. 
Treatment is tailored to the patient’s suffering 
and not just treats the loss of urine. In other words, a 
successful therapy includes the main objective 
parameters (dry/wet) and the subjective quality of life 
which is assessed by questionnaires [16]. However, 
understanding the "results" and the statistical methods 
used in their quantification are not homogeneous and 
sufficiently clear in order to remove any controversy. 
Before we compare and decide which is the most 
effective procedure, we should reach a consensus on the 
definition of "results", how they should be measured, 
follow-up intervals, etc. Until these issues are clarified, the 
urologist will continue to choose one of the many existing 
procedure and will remain autonomous in his selection. 
Thus, the need for new therapeutic methods, that can 
restore as close as possible the integrity of the pelvic 
structures, is urgently required.  
Conclusions 
Stem-cell- mioblasts therapy may represent in 
the future an every-day intervention in the urologist’s 
armamentarium. At least for this group of patients, to 
whom, from the pathogenic point of view, the deficiency is 
limited to the urethral sphincter, part of the excretory 
system, we believe that the urologist’s interest should be 
maximal. The effectiveness of this treatment can change 
the course of therapy and last but not least, the 
accessibility to urological evaluation of patients with stress 
urinary incontinence. 
The Centers of Excellence in Urology must 
develop research programs and become partners in 
multicenter studies in order to obtain solid long term data. 
Thus, new standards will be created that will be approved 
by urologists everywhere. 
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